- Pfizer Inc (NYSE:PFE) would supply up to 6 million courses of its COVID-19 antiviral treatment to NGO Global Fund for low- and middle-income countries.
- The company said Paxlovid treatment courses would be available for procurement through Global Fund’s COVID-19 Response Mechanism to 132 low- and middle-income countries this year, subject to local regulatory clearances.
- Eligible countries will be offered treatment courses according to Pfizer’s tiered pricing approach, where all low- and lower-middle-income countries will pay a not-for-profit price.
- Also Read: Pfizer’s COVID-19 Pill Benefited Only Older Adults, New Israel-Based Study Shows.
- Additional contractual details of the agreement were not disclosed.
- Pfizer has made a deal with several generic drugmakers to produce its treatment at a lower price for developing countries.
- “This agreement with Global Fund is a critical step that will boost equitable access for high-risk patients in low-and-middle-income countries,” Chief Executive Officer Albert Bourla said in a statement.
- Price Action: PFE shares are up 1.24% at $44.47 on the last check Thursday.
- Photo via Wikimedia Commons
NRx Pharmaceuticals Publishes Shareholder Update Letter; Update Highlights Potential Implications Of The Company’s Recent Activities At The Annual Meeting Of The American Society Of Clinical Psychopharmacology
The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating
